Market revenue in 2023 | USD 1,422.9 million |
Market revenue in 2030 | USD 4,122.5 million |
Growth rate | 16.4% (CAGR from 2023 to 2030) |
Largest segment | Reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Reagents, Kits, Instruments, Enzymes, Services |
Key market players worldwide | Roche Holding AG, Thermo Fisher Scientific Inc, Eisai Co Ltd, Novartis AG ADR, Element Biosciences, Dovetail Genomics, Illumina Inc, Promega, Abcam PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to epigenetics market will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 33.4% in 2023. Horizon Databook has segmented the Germany epigenetics market based on reagents, kits, instruments, enzymes, services covering the revenue growth of each sub-segment from 2018 to 2030.
Germany, a major player in the biotechnology & pharmaceutical sectors in Europe, plays a significant role in developing and applying gene editing technologies, including epigenetics. The epigenetics market in Germany is influenced by various factors such as R&D initiatives, regulatory frameworks, and collaborations between academic institutions & industry.
For instance, in January 2023, Asklepios Bio-Pharmaceutical, Inc. and Re-Code Therapeutics announced a strategic collaboration to explore a novel gene editing platform using Re-Code's proprietary single-vector delivery technology.
This partnership aimed to develop a new method for delivering gene editing tools and gene cargo into cells, potentially leading to innovative gene therapies. Some key players in Germany epigenetics market are CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Sangamo Therapeutics.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany epigenetics market , including forecasts for subscribers. This country databook contains high-level insights into Germany epigenetics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account